FOLFIRI


Also found in: Medical, Wikipedia.
AcronymDefinition
FOLFIRIFolinic Acid, Fluorouracil & Irinotecan (chemo treatment)
References in periodicals archive ?
[120], 340 KRAS exon-2 wild-type metastatic CRC patients received first-line cetuximab plus FOLFIRI. Tumor samples were analysed using NGS while BEAMing (digital PCR technology combines emulsion PCR with magnetic beads and flow cytometry for the highly sensitive detection and quantification of mutant tumor DNA molecules) has been used to search for KRAS and NRAS mutations in plasma samples.
Decker et al., "Folfiri plus cetuximab versus folfiri plus bevacizumab as first-line treatment for patients with metastatic colorectal cancer (fire-3): a randomised, open-label, phase 3 trial," The Lancet Oncology, vol.
Patients in arm S were treated with 5-fluorouracil and leucovorin (LV5FU2) in first line, then with FOLFOX (LV5FU2 + oxaliplatin) in second line, and then with FOLFIRI (LV5FU2 + irinotecan) in third line.
Yukimatsu et al., "A case of metastatic urachal carcinoma treated with FOLFIRI (irinotecan and 5-fluorouracil/leucovorin) plus bevacizumab," Urology Case Reports, vol.
Because of the considered histological and clinical similarities between colorectal and urachal carcinoma, his treatment was changed to FOLFIRI (i.v.
We selected a FOLFIRI (irinotecan, folinic acid, and fluorouracil) plus bevacizumab regimen as neoadjuvant chemotherapy, considering the mutant KRAS status.
After a follow-up of 3 years, the chemotherapy regimen was changed to FOLFIRI (Leucovorin Calcium, Fluorouracil, Irinotecan Hydrochloride).
A few days later, a CT-guided biopsy was performed, after which the chemotherapy regimen was changed to chronomodulated bevacizumab plus irinotecan with fluorouracil and folinic acid (FOLFIRI).
Patients in the control group were treated with chemotherapy alone using either FOLFOX (LOHP at 85mg/[m.sup.2] on day 1 + CF at 200mg/[m.sup.2] on days 1 and 2 + 5-FU at 400mg/[m.sup.2] on days 1 and 2 + 5-FU at 1200 mg/[m.sup.2] in a continuous intravenous infusion for 44 h every 14 days) or FOLFIRI (CPT-11 at 180 mg/[m.sup.2] on day 1 + CF at 200mg/[m.sup.2] on days 1 and 2 + 5-FU at 400 mg/[m.sup.2] on days 1 and 2 + 5-FU at 1200 mg/[m.sup.2] in a continuous intravenous infusion for 44 h every 14 days).